https://www.selleckchem.com/products/ly333531.html After adjustment, men with BMI ≥ 30 kg/m2 had an increased risk of prostate cancer relative to men with BMI less then  25 kg/m2 (OR 1.86, 95% CI 1.11-3.13). Elevated WC (OR 1.76, 95% CI 1.24-2.51) and WHR (OR 1.46, 95% CI 0.99-2.16) were also associated with prostate cancer. Associations were not modified by smoking status and were evident for low- and high-grade disease. These findings indicate that overall and abdominal obesity are positively associated with prostate cancer among men in Ghana, implicating obesity as a potentially modifiable risk factor for prostate cancer in this region. © 2020 UICC.COVID-19 is overshadowing society across the world and it will redefine many aspects of how we live and work in the future. In a crisis, people are rightly looking for solutions from their leaders and experts and their response and actions will define them for years to come. COVID-19 may also be such a defining moment for clinical pharmacology in terms of its role in drug development and therapy. Though most drug development takes years from discovery to approval, for the COVID-19 pandemic, drug development is on a fundamentally different timeline. This article is protected by copyright. All rights reserved.We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID-191 . We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS-CoV-2 are 10-60 µg/ml and 9.4 µg/ml4 , respectively. However results obtained by our working group suggest a higher value of EC50 , in the range 40-80 µg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS-CoV-2 is in the same range as against EBOV. This article is protected by copyright. All rights reserved.Additional to the problems described very well by Dr. Ioannidis1 , ther